We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AbCellera Biologics Inc. (ABCL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
AbCellera Biologics Inc. is one of 884 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABCL's full-year earnings has moved 25.1% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ABCL has moved about 80.4% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 5.2% on average. This means that AbCellera Biologics Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is C4 Therapeutics, Inc. (CCCC - Free Report) . The stock is up 128.8% year-to-date.
For C4 Therapeutics, Inc., the consensus EPS estimate for the current year has increased 14.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 430 individual stocks and currently sits at #149 in the Zacks Industry Rank. This group has gained an average of 0.3% so far this year, so ABCL is performing better in this area. C4 Therapeutics, Inc. is also part of the same industry.
AbCellera Biologics Inc. and C4 Therapeutics, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AbCellera Biologics Inc. (ABCL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
AbCellera Biologics Inc. is one of 884 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABCL's full-year earnings has moved 25.1% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ABCL has moved about 80.4% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 5.2% on average. This means that AbCellera Biologics Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is C4 Therapeutics, Inc. (CCCC - Free Report) . The stock is up 128.8% year-to-date.
For C4 Therapeutics, Inc., the consensus EPS estimate for the current year has increased 14.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 430 individual stocks and currently sits at #149 in the Zacks Industry Rank. This group has gained an average of 0.3% so far this year, so ABCL is performing better in this area. C4 Therapeutics, Inc. is also part of the same industry.
AbCellera Biologics Inc. and C4 Therapeutics, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.